Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group

References

• Stone R M, Mayer R J. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hemat Oncol Clin North Am 1993; 7: 47–63
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Downing J R, Burnett A. Medical progress: acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062
   PubMed Web of Science ®Google Scholar
• Berman E. Chemotherapy in acute myelogenous leukemia: High dose, higher expectations?. J Clin Oncol 1995; 13: 1–4
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674
   PubMed Web of Science ®Google Scholar
• Mandelli F, Petti M C, Ardia A, Di Pietro N, Di Raimondo F, Ganzina F, et al. A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukemia. European J Cancer 1991; 27: 750–755
   PubMed Web of Science ®Google Scholar
• Reiffers J, Huguet F, Stoppa A M, Michallet M, Hurteloup P. Intensive induction chemotherapy in elderly patients. Br J Hematol 1992; 82: 175–176
   PubMed Web of Science ®Google Scholar
• Vogler W R, Velez-Garcia E, Weiner R S, Flaum M A, Bartolucci A A, Omura G A, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southern Cancer Study Group study. J Clin Oncol 1992; 10: 1103–1111
   PubMed Web of Science ®Google Scholar
• Wiernik P H, Banks P LC, Case, Jr, et al. Cytarabine plus idarubicin or daunorubicin or induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–319
   PubMed Web of Science ®Google Scholar
• Bishop J F, Lowenthal R, Joshua D, Mathews J P, Wolf M M, Cooper I A. Etoposide in leukemia. Cancer 1991; 67: 285–291
   PubMed Web of Science ®Google Scholar
• Bow E J, Sutherland J A, Kilpatrick M G, Williams G J, Clinch J J, Shore T B, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Onc 1996; 14: 1345–1352
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Morra E, Allessandrino E P, Orlandi E, Pagnucco G, Merante S, et al. Mitoxantrone and etoposide: An effective regimen for refractory or relapsed acute myelogenous leukemia. Eur J Haematol 1989; 43: 411–416
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, et al. Mitoxantrone and High-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 1991; 68: 691–694
   PubMed Web of Science ®Google Scholar
• Ho A D, Lipp T, Ehninjer G, Illiger H J, Meyer P, Freund M, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia. An active and well tolerated regimen. J Clin Oncol 1988; 6: 213–217
   PubMed Web of Science ®Google Scholar
• Paciucci P A, Davis R B, Holland J F, Martelo O, Schiffer C A. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol 1990; 13: 516–519
   PubMed Web of Science ®Google Scholar
• Daenen S, Lowenberg B, Sonneveld P, van Putten W L, Verhoef G, Verdonck L F, et al. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). Leukemia 1994; 8: 6–10
   PubMed Web of Science ®Google Scholar
• Ho A D, Brado B, Haas R, Del Valle F, Burke K, Hunstein W. Sequential therapy with idarubicin/cytarabine and mitoxantrone/etoposide for adult acute myelogenous leukemia – a pilot study. Blood 1990; 76(suppl 1)280a
   Google Scholar
• Haas R, Schneeweib A, Brado B, Witt B, Hunstein W, Del Valle F, et al. Induction therapy for acute myelogenous leukemia with idarubicin/cytosine arabinoside and mitoxantrone/etoposide in “response-adapted” sequence. Haematol and Blood Transfusion 1992; 34: 439–444
   Google Scholar
• Haas R, Ho A D, Del Valle F, Fischer J T, Ehrhardt R, Dohner H, et al. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Semin Oncol 1993; 20(Suppl 8)20–26
   PubMed Web of Science ®Google Scholar
• DRUGDEX® System, T A Hutchison, D R Shahan, M L Anderson. MICROMEDEX, Inc, Englewood, Colorado, Edition expires 11/2000
   Google Scholar
• Twelves C J, Dobbs N A, Michael Y, Summers L A, Gregory W, Harper P G, et al. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 1992; 66: 765–769
   PubMed Web of Science ®Google Scholar
• Daghestani A N, Zalmen A A, Leyland Jones B, Gee T S, Kempin S J, Mertelsmann R, et al. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubcin) in adult patients with acute leukemia. Cancer Res 1985; 45: 1408–1412
   PubMed Web of Science ®Google Scholar
• Cheson B D, Cassileth P A, Head D R, Schiffer C A, Bennett J M, Bloomfield C D, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813–819
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Non-parametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Karanes C, Kopecky K J, Head D R, Grever M R, Hynes H E, Kraut E H, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 1999; 23: 787–794
   PubMed Web of Science ®Google Scholar
• Bishop J F. Approaches to induction chemotherapy with adult acute myeloid leukaemia. Acta Haematol 1998; 99: 133–137
   PubMed Web of Science ®Google Scholar
• Strategies other than dose-intensification should be pursued in elderly patients with untreated acute myeloblastic leukemia. Haematologica 2002; 87: 786
   Google Scholar
• Bishop J F, Matthews J P, Young G A, Szer J, Gillett A, Joshua D, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710–1717
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 1999; 70: 97–104
   PubMed Web of Science ®Google Scholar
• Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896
   PubMed Web of Science ®Google Scholar
• Cassileth P A, Harrington D P, Appelbaum F R, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656
   PubMed Web of Science ®Google Scholar
• Stone R M, Berg D T, George S L, Dodge R K, Paciucci P A, Schulman P P, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate dose cytarabine with standard dose cytarabine. Blood 2001; 98: 548–553
   PubMed Web of Science ®Google Scholar
• Anderson J E, Kopecky K J, Willman C L, Head D, O'Donnell M R, Luthardt F W, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group Study. Blood 2002; 100: 3869–3876
   PubMed Web of Science ®Google Scholar
• Mrozek K, Heinonen K, Bloomfield C D. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 19–47
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood 1998; 92: 2322
   PubMed Web of Science ®Google Scholar
• Visani G, Bernasconi P, Boni M, Castoldi G L, Ciolli S, Clavio M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. Leukemia 2001; 15: 903–909
   PubMed Web of Science ®Google Scholar
• Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to therapy. A Southwest Oncology Group Study. Blood 1997; 89: 3323
   PubMed Web of Science ®Google Scholar
• Goldstone A H, Burnett A K, Wheatley K, Smith A G, Hutchinson R M, Clark R E, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302–1311
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64–70
   PubMed Web of Science ®Google Scholar
• Anderlini P, Ghaddar H M, Smith T L, Pierce S, Kantarjian H M, O'Brien S, et al. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 1996; 10: 964–969
   PubMed Web of Science ®Google Scholar
• Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L, et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. Bone Marrow Trans 1996; 17: 993–1001
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, et al. Timed sequential chemotherapy for previously treated with acute myeloid leukemia: Long-term follow-up of the etoposide, Mitoxantrone and cytarabine - 86 Trial. J Clin Oncol 1995; 13: 11–18
   PubMed Web of Science ®Google Scholar
• Woods W G, Kobrinsky N, Buckle J, Lee J W, Sanders J, Neudorf S, Gold S, et al. Timed-sequential induction therapy improves post remission outcome in acute myeloid leukemia: a report from the Children's Cancer Study Group. Blood 1996; 87: 4979–4989
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, et al. Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004; 104: 2467–2474
   PubMed Web of Science ®Google Scholar
• Lampkin B, Nagao T, Maven A. Synchronization and recruitment in acute leukemia. J Clin Invest 1971; 50: 2204
   PubMed Web of Science ®Google Scholar
• AML Collaborative Group. A systematic overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukemia. Br J Haematol 1998; 103: 100–109
   PubMed Web of Science ®Google Scholar
• van der Jagt R, Robinson S, Gluck S, Belch A, Sheridan D, Matthews J, et al. Response-adapted treatment of de novo acute myelobalstic leukemia: A phase II multicentre study of sequential induction regimens idarubicin/cytarabine and mitroxantrone/etoposide. Blood 1995; 86(Suppl 1)180
   Google Scholar
• van der Jagt R, Robinson K S, Sheridan D P, Delage R, Larratt L M, Wells G A, et al. A multicenter randomized trial comparing response-adapted (RA), non-cross-resistant induction and consolidation with idarubicin/cytarabine (IDAC) followed by mitoxantrone/etoposide (NOVE) compared with consolidation with high dose cytarabine (HDAC) in adult patients with AML. A study by the Canadian Leukemia Studies Group (CLSG). Blood 2002; 100: 344a
   PubMed Web of Science ®Google Scholar